CVS Health won't cover Gilead's new HIV prevention drug Yeztugo

CVS Health, the largest U.S. pharmacy benefit manager, will not include Gilead Sciences' new HIV prevention drug Yeztugo in its commercial or Affordable Care Act formularies, citing clinical, financial, and regulatory considerations, including current HHS guidelines that only cover older medications. This decision, despite the drug's proven effectiveness and annual list price exceeding $28,000, underscores the significant leverage PBMs hold over drug access and pricing, prompting concerns from advocates about the sustainability of high pharmaceutical costs in the U.S.

Analysis

Gilead Sciences (GILD) faces a significant commercial hurdle as CVS Health (CVS), the largest U.S. pharmacy benefit manager, has opted not to include the new HIV prevention drug, Yeztugo, in its commercial formularies. This decision, attributed to clinical, financial, and regulatory factors, directly impacts the market access for a drug with an annual list price exceeding $28,000. The exclusion from CVS's Affordable Care Act plans is particularly notable, as it is based on current U.S. Preventive Services Task Force guidelines that only recommend three older medications, underscoring the high barrier for new, premium-priced drugs to gain mandated coverage. While negotiations between Gilead and CVS are reportedly ongoing, the public refusal signals strong payer resistance to high-cost pharmaceuticals, a sentiment echoed by advocacy groups criticizing the U.S. drug pricing structure. This development is a distinct negative for Gilead, reflected in its negative sentiment score (-0.5), as it threatens the sales trajectory of a key new product, while for CVS, it is a neutral event (sentiment score 0.0) that showcases its negotiating power and focus on cost containment.

Key Decisions for Investors

• Investors in Gilead Sciences should consider the heightened risk to Yeztugo's revenue forecast given that access to the largest U.S. PBM is currently blocked, and should monitor ongoing negotiations for any change in status.
• This event highlights the systemic risk of payer pushback against high-cost therapies, prompting a need to re-evaluate pricing power assumptions for other assets in Gilead's pipeline.
• For CVS, the decision reinforces its formidable market power as a pharmacy benefit manager, which is a key positive for its ability to manage costs and maintain margins in its healthcare benefits segment.